Summary
Pfizer Inc.'s 2009 10-K filing reveals a pivotal year marked by the transformative acquisition of Wyeth in October 2009. This strategic move significantly diversified Pfizer's healthcare portfolio, integrating human and animal health products, vaccines, biologics, small molecules, and nutritional offerings. The company is now better positioned in key therapeutic areas such as oncology, pain, inflammation, and Alzheimer's disease, while also aiming to be a top-tier player in biotherapeutics and accelerate growth in emerging markets. Despite the successful integration of Wyeth, Pfizer faced challenges including the ongoing impact of foreign currency fluctuations and generic competition for established products like Lipitor and Norvasc. The company's robust research and development pipeline, with a substantial investment of $7.8 billion in 2009, remains a critical driver for future growth, focusing on addressing significant unmet medical needs. Investors should monitor the ongoing integration efforts, the performance of new and existing product lines, and the impact of regulatory and competitive pressures in the evolving pharmaceutical landscape.
Financial Highlights
51 data points| Revenue | $49.27B |
| Cost of Revenue | $8.46B |
| Gross Profit | $40.81B |
| SG&A Expenses | $14.75B |
| Operating Income | $8.52B |
| Interest Expense | $1.23B |
| Net Income | $8.63B |
| EPS (Basic) | $1.23 |
| EPS (Diluted) | $1.23 |
| Shares Outstanding (Basic) | 7.01B |
| Shares Outstanding (Diluted) | 7.04B |
Key Highlights
- 1Acquisition of Wyeth for approximately $68 billion in October 2009, significantly expanding and diversifying Pfizer's product portfolio and market reach.
- 2Biopharmaceutical segment accounted for approximately 91% of total revenues in 2009, with nine legacy Pfizer products exceeding $1 billion in sales.
- 3Significant investment in Research and Development (R&D) totaling $7.8 billion in 2009, supporting a pipeline of approximately 500 projects.
- 4International operations contributed 57% of total revenues in 2009, with the U.S. being the largest single market.
- 5Facing patent expirations and ongoing generic competition for key products such as Lipitor, Norvasc, and Effexor XR.
- 6Continued efforts to manage costs and streamline operations, including a global initiative to reduce the office real estate portfolio by year-end 2012.
- 7The company is subject to extensive government regulation and faces pricing pressures in both domestic and international markets.